Study Data Reviewer’s Guide

LDCP, Inc.
Study LDCP-0242-005
Version 2017-10-12
Study LDCP-0242-005 Study Data Reviewer’s Guide

Study Data Reviewer’s Guide

Contents
1. Introduction.........................................................................................................................................3
1.1 Purpose........................................................................................................................................3
1.2 Acronyms....................................................................................................................................3
1.3 Study Data Standards and Dictionary Inventory..........................................................................4
2. Protocol Description............................................................................................................................4
2.1 Protocol Number and Title...........................................................................................................4
2.2 Protocol Design...........................................................................................................................4
2.3 Trial Design Datasets...................................................................................................................5
2.3.1. TI – Trial Inclusion/Exclusion Criteria................................................................................5
2.3.2. TS – Trial Summary.............................................................................................................5
3. Subject Data Description.....................................................................................................................5
3.1 Overview.....................................................................................................................................5
3.2 Annotated CRFs..........................................................................................................................6
3.3 SDTM Subject Domains..............................................................................................................6
3.3.1. CM – Concomitant Medications..........................................................................................7
3.3.2. DS – Disposition..................................................................................................................7
3.3.3. EX – Exposure.....................................................................................................................7
3.3.4. LB – Laboratory Test Results...............................................................................................7
3.3.6. VS – Vital Signs...................................................................................................................7
4. Data Conformance Summary..............................................................................................................8
4.1 Conformance Inputs.....................................................................................................................8
4.2 Issues Summary...........................................................................................................................8
Appendix I: Inclusion/Exclusion Criteria....................................................................................................9
Legacy Data Conversion Plan and Report Appendix.................................................................................10
1. Purpose..............................................................................................................................................10
2. Conversion Data Flow.......................................................................................................................10
3. Converted Data Summary..................................................................................................................11
3.1 Issues Encountered and Resolved....................................................................................................11
4. Traceability Data Flow......................................................................................................................12
5. Outstanding Issues.............................................................................................................................12
Appendix II: Lab test Look-up Table........................................................................................................15

PDF created 2017-12-12 Page 2 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

PDF created 2017-12-12 Page 3 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

1. Introduction

1.1 Purpose
This document provides context for tabulation datasets and terminology that benefit from additional
explanation beyond the Data Definitions document (define.xml). In addition, this document
provides a summary of SDTM compliance findings as well as details regarding legacy data
conversion to SDTM.

1.2 Acronyms
Acronym Translation
ADaM Analysis Data Model
CDISC Clinical Data Interchange Standards Consortium
CRF Case Report Form
CRU Clinical Research Unit
CT Controlled Terminology
ECG Electrocardiography
eDT Electronic Data Transfer
MedDRA Medical Dictionary for Regulatory Activities
PK Pharmacokinetics
SDTM Study Data Tabulation Model
SDTM-IG Study Data Tabulation Model Implementation Guide
SNOMED Systematized Nomenclature of Medicine
XML Extensible Markup Language

1.3 Study Data Standards and Dictionary Inventory

Standard or Dictionary Versions Used

SDTM SDTM v1.3/SDTMIG v3.1.3

PDF created 2017-12-12 Page 4 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

Standard or Dictionary Versions Used

Controlled Terminology 2016-03-25
Data Definitions define.xml v2.0
Medications Dictionary Proprietary medication dictionary
Medical Events Dictionary MedDRA v14.1

2. Protocol Description

2.1 Protocol Number and Title

Protocol Number: LDCP-0242-005
Protocol Title: A Phase II, Randomized Double-Blind Placebo-Controlled Dose Ranging
Study to Evaluate LDCP-0242 in Adults with Asthma
Protocol Versions: LDCP-0242-005 v1.0

2.2 Protocol Design

LDCP-0242

2.3 Trial Design Datasets

Are Trial Design datasets included in the submission? Yes

PDF created 2017-12-12 Page 5 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

2.3.1. TI – Trial Inclusion/Exclusion Criteria

The trial inclusion/exclusion criteria are not fully described in the TI domain. Please refer to
Appendix I for the full text of the criteria.
2.3.2. TS – Trial Summary
The TS domain includes the deprecated parameter Adverse Events Dictionary (AEDICT) to support
internal processes.

3. Subject Data Description

3.1 Overview
Are the submitted data taken from an ongoing study? No
If yes, describe the data cut or database status:
Were the SDTM datasets used as sources for the analysis datasets? No
If no, what were the sources of analysis datasets? Legacy tabulation data
Please refer to Section 5 for details: Clinical Legacy Data Conversion Plan and Report
Do the submission datasets include screen failures? Yes
If yes, which datasets include screen failure data?
Screen failure data are found in the DM, IE, DS and AE datasets.
Were any domains planned, but not submitted because no data were collected? No
If yes, list domains not submitted:
Are the submitted data a subset of collected data? No
If yes, describe:

Additional Content of Interest

Key analysis data points include:
 Spirometry endponts: RE domain where RECAT = SPIROMETRY and RENAM = SPIRO-
GRAPH
 Asthma exacerbation endpoints: RE domain where RECAT = ASTHMA
EXACERBATIONS and QS domain where QSTESTCD = QS12379A
 Safety analysis: AE domain
 Subject deaths: AE domain where AEOUT = FATAL, DS domain where DSSCAT = STUDY
DISCONTINUATION and DSDECOD = DEATH
Reference start date was assigned as the date of first dose of study medication and will be missing for
screening failures as well as subjects that were randomized but not treated.
A CRF collected pregnancy event information; however, no pregnancy events were reported.

PDF created 2017-12-12 Page 6 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

3.2 Annotated CRFs

Collected fields that have not been tabulated have been annotated as “NOT SUBMITTED”. LDCP,
Inc. collects certain data elements (e.g. prompt questions) to facilitate certain operational processes
including data cleaning and dynamically creating additional forms in the electronic data capture
(eDC) system. All fields that have been annotated as “NOT SUBMITTED” meet these criteria.

3.3 SDTM Subject Domains

Efficacy
Related

SUPP-
Safety

Other
Using Observation
Dataset – Dataset Label RELREC Class
AE – Adverse Events X RE Events

CM – Concomitant Medications X X Interventions

CO – Comments X Special Purpose

DM – Demographics X Special Purpose

DS – Disposition X Events

EX – Exposure X Interventions

LB – Laboratory Test Results X X X Findings

MH – Medical History X Events

QS – Questionnaires X X Findings

RE – Respiratory System Findings X X X AE Findings

SE – Subject Elements X Special Purpose

SV – Subject Visits X Special Purpose

VS – Vital Signs X Findings

3.3.1. CM – Concomitant Medications
The start date for historical corticosteroids was not reported for 37 subjects. As a result, validation
rule errors are to be expected.
3.3.2. DS – Disposition
After a subject completes the trial, two observations with DSCAT equal to DISPOSITION EVENT
are expected. DSSCAT = ‘TREATMENT DISCONTINUATION’ indicates the subject’s completion
status relative to Day 85. DSSCAT = ‘STUDY DISCONTINUATION’ indicates the subject’s
completion status at study exit.
3.3.3. EX – Exposure

PDF created 2017-12-12 Page 7 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

Four LDCP-0242/Placebo injections were planned at each visit. Each injection is recorded as a
separate observation in the EX domain. The total dose received at each visit can be calculated by
summing the individual doses at each visit. If LDCP-0242/Placebo was not administered at a visit, an
observation has been recorded in EX for that visit and EXOCCUR assigned to N.
3.3.4. LB – Laboratory Test Results

QNAM Description
LBCVRESC Character result in conventional units
LBCVRESU Conventional unit
LBCVNRLO Reference range lower limit in conventional units
LBCVNRHI Reference ranges upper limit in conventional units

3.3.5. RE – Respiratory System Findings

RE is a CDISC draft body-system domain that is not yet finalized and will be considered a custom
domain until such time. It contains data pertaining to the investigator’s assessment of the
interventions and asthma-related symptoms indicative of an exacerbation event. The considerations
for this assessment are defined in the protocol. If the investigator believes an asthma exacerbation
event has occurred, the investigator will record this as an adverse event. An explicit link has been
collected between the assessment and the corresponding adverse event. This relationship between RE
and AE is defined in RELREC.
RE also contains data collected in relation to spirometry assessments.

3.3.6. VS – Vital Signs

Temperature was not collected prior to randomization; therefore, --BLFL will be missing for all
observations where VSTESTCD = ‘TEMP’.

PDF created 2017-12-12 Page 8 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

4. Data Conformance Summary

4.1 Conformance Inputs

Was Pinnacle21 Community/Enterprise used to evaluate conformance? Yes
If yes, specify the versions of the validator and validation rules:
Pinnacle21 Community v2.2.0, SDTM 3.1.3 (FDA)
Were sponsor-defined validation rules used to evaluate conformance?No
If yes, describe any significant sponsor-defined validation rules:
Were the SDTM datasets evaluated in relation to define.xml? Yes
Was define.xml evaluated? Yes
Provide any additional compliance evaluation information:

4.2 Issues Summary

Dataset Diagnostic Message Severity Count Explanation

CM Start Date/Time of Observation Warning 37 The start date for historical
(--STDTC) or Start Relative to corticosteroids was not
Reference Period (--STRF) reported for 37 subjects.
should not be NULL, when
End Date/Time of Observation
(--ENDTC) or End Relative to
Reference Period (--ENRF) is
not NULL

PDF created 2017-12-12 Page 9 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

Appendix I: Inclusion/Exclusion Criteria

Protocol/
Amendment
Version Category IETESTCD Full Text of Criterion
SDRG-001A INCLUSION INCL01 Signed Informed Consent
SDRG-001A INCLUSION INCL02 Age >= 18 years and <= 65 years at Screening Visit
SDRG-001A INCLUSION INCL03 Body Weight >=50 kg and <=150 kg at Screening Visit
SDRG-001A INCLUSION INCL04 Stable asthma defined by the following criteria.
1. Diagnosis of asthma >= 12 months prior to Screening Visit
2. Bronchodilator response of a minimum of 15% relative increase in the volume of FEV1
after bronchodilator at Visit 1 or Visit 2
3. Prebronchodilator FEV1 >=60% and <=85% predicted at Visit 2.
SDRG-001A EXCLUSION EXCL01 Basal or squamous cell carcinoma
SDRG-001A EXCLUSION EXCL02 Known immunodeficiency including but not limited to HIV infection
SDRG-001A EXCLUSION EXCL03 Noncompliance or inability to participate in all assessments

PDF created 2017-12-12 Page 10 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

Legacy Data Conversion Plan and Report Appendix

1. Purpose
The purpose of this appendix is to document the legacy tabulation data conversion to SDTM.

2. Conversion Data Flow

The legacy data was converted to SDTM as described in the following data flow diagram.

eCRF
Data

Tabulation Analysis Output Results

Data Data
eDT*
Data

Annotated
CRF

SDTM

*eDT = Electronic Data Transfer (e.g. central lab data, ECG vendor data, PK data, etc)

Rationale:
The legacy data was converted to SDTM without creating ADaM datasets since the study started before
December 17, 2016. The rationale for only converting to SDTM was to support pooling activities for the
ISS and ISE. The tabulation data was pooled at the SDTM level and ADaM datasets were created to be
used as input for the ISS/ISE.

PDF created 2017-12-12 Page 11 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

2. Converted Data Summary

The legacy data was available in SAS format (.sas7bdat). A formats catalog was applied to the datasets
prior to conversion to SDTM in order to aid in source-to-target mapping (e.g. straight map or minimal
conditional statements needed). During authoring of the mapping specification from legacy data to
SDTM, CDISC Controlled Terminology was applied where applicable. After authoring of a mapping
specification and programming of the SDTM SAS datasets, the Pinnacle21 validator was run to check
compliance to SDTMIG v3.1.3. Any checks that signified a programming issue were addressed and the
relevant SDTM datasets were updated.
After resolution of all validation issues that could be fixed, a QC step was performed where the datasets
were double-programmed by a separate QC programmer using the mapping spec as a reference. Any
fallouts were recorded per the sponsor’s SOPs and returned to the SDTM programmer for updates. After
confirmation that updates were applied properly, the SDTM data was considered complete and sent to a
publishing programmer for creation of the SDTM annotated CRF as well as the define.xml. Each of these
tasks included QC steps as well.

3.1 Issues Encountered and Resolved

 MedDRA v14.1 was used to encode adverse events in the legacy data for this study. This version was
retained when mapped to the SDTM AE domain to maintain traceability to the CSR. Terms will be re-
coded to MedDRA v20.0 at the pooled SDTM level per advice in the Technical Conformance Guide
to encode to one version of the dictionary. A lookup table from source to target terms will be
provided with pooled SDTM datasets for the ISS.
 A proprietary drug dictionary was used to encode data for prior/concomitant medications in the
legacy data for this study. This dictionary was retained when mapped to the SDTM CM domain to
maintain traceability to the CSR. Medications will be re-coded to WHODrug March 2017 at the
pooled SDTM level per advice in the Technical Conformance Guide to encode to one version of the
dictionary. A lookup table from source to target terms will be provided with pooled SDTM datasets
for the ISS.
 Lab normal ranges were not in the same legacy dataset as the lab tests and results. Normal ranges had
to be merged with the lab dataset. QC steps were performed to ensure that ranges were applied
appropriately.

PDF created 2017-12-12 Page 12 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

3. Traceability Data Flow

eCRF
Data

Legacy Legacy Legacy Output

Tabulation Analysis
Data
Results
Data
eDT*
Data

Annotated
CRF
SDTM

Pooled Output
Pooled Pooled Results
SDTM ADaM

*eDT = Electronic Data Transfer (e.g. central lab data, ECG vendor data, PK data, etc)

The legacy datasets, legacy aCRF, and legacy define.pdf have been provided in the ‘legacy’ folder.

4. Outstanding Issues
 SDTM DM.RACE: Eight race values were collected on the CRF for this study and mapped to only 5
races in SDTM since the CDISC CT RACE codelist is non-extensible. Not all DM Race values will
be traceable to the CSR. A lookup table is provided below to convey the mapping done for race from
legacy values to SDTM. For values of race that do not directly map to a standardized race value (e.g.

PDF created 2017-12-12 Page 13 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

‘Japanese’ to ‘ASIAN’), the original race value was also retained in SUPPDM.QVAL where QNAM
= ‘RACEOR’.
CRF Collected Race Count SDTM RACE Count
White/Caucasian 145 WHITE 145
BLACK OR AFRICAN
Black or African American 112 112
AMERICAN
Asian Indian 50
Japanese 30
ASIAN 135
Chinese 40
Korean 15
Native Hawaiian 57 NATIVE HAWAIIAN OR OTHER
83
Other Pacific Islander 26 PACIFIC ISLANDER
AMERICAN INDIAN OR
Alaskan Native or American Indian 34 34
ALASKA NATIVE

 SDTM DS.DSDECOD: Eleven disposition terms were collected on the eCRF but all did not map
directly to DS.DSDECOD from the CDISC CT NCOMPLT codelist. Not all terms will be traceable
to the CSR. A lookup table is provided below to convey the mapping done for subject disposition
from legacy values to SDTM DSDECOD in the DS domain. For values that do not map directly, the
original term captured will be retained in the DSTERM variable.

CRF Collected Disposition Count SDTM DSDECOD Count

Completed 325 COMPLETED 325
Need for Excluded Medication 42
Treatment Unblinded 2
Non-Compliance With OTHER 82
33
Protocol
Lack of Qualifying Event 5
WITHDRAWAL BY
Subject Withdrew Consent 15 15
SUBJECT
Physician Discontinued Subject 8 PHYSICIAN DECISION 8
Treatment Failure 22 LACK OF EFFICACY 22
Adverse Event 53 ADVERSE EVENT 53
Lost to Follow-Up 3 LOST TO FOLLOW-UP 3
Death 1 DEATH 1
 Legacy lab test names and units will match names in CSR listings but will not match the lab test
names and units in the SDTM LB dataset. In SDTM LB, CDISC Controlled Terminology was
applied. This was done in order to easily pool the data with other studies included in the ISS. The

PDF created 2017-12-12 Page 14 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

LBTESTCD/LBTESTs present in the SDTM data are listed in the define.xml. Please see Appendix II
for Lab lookup table that maps legacy test names to SDTM CT to provide traceability from legacy to
SDTM.

PDF created 2017-12-12 Page 15 of 16

Study LDCP-0242-005 Study Data Reviewer’s Guide

Appendix II: Lab test Look-up Table

Source Test Code Source Test Name SDTM_LBTESTCD SDTM_LBTEST SDTM_LBSPEC

BILITOT Total Bilirubin BILI Bilirubin SERUM
BRALCOHL Alcohol Breath Test ETHANOL Ethanol BREATH
BASO_P Basophils (Percent) BASOLE Basophils/Leukocytes BLOOD
EOS_P Eosinophils (Percent) EOSLE Eosinophils/Leukocytes BLOOD
HEPCAB Hepatitis C Antibody HCAB Hepatitis C Virus Antibody SERUM
MONO_P Monocytes (Percent) MONOLE Monocytes/Leukocytes BLOOD
NA Sodium SODIUM Sodium SERUM
NEUT_P Neutrophils (Percent) NEUTLE Neutrophils/Leukocytes BLOOD
PROTOT Total Protein PROT Protein SERUM
PTINR Prothrombin Time INR INR Prothrombin Intl. Normalized Ratio BLOOD
BILICY Bilirubin Crystals CYBILI Bilirubin Crystals URINE
PROT Urine Protein PROT Protein URINE
UGLUC Urine Glucose GLUC Glucose URINE

PDF created 2017-12-12 Page 16 of 16